FDA fast-tracks new Gleevec use

Earlier this week, Novartis got FDA priority review for Gleevec, its cancer med, for treatment of gastrointestinal stromal tumors after surgery. The agency will say "yea" or "nay" on the new indication within six months, rather than the typical 10. According to Novartis research, Gleevec cut the risk of tumors returning after surgery by 89 percent. Report